Reported 29 days ago
Pfizer's CEO Albert Bourla defended the company's turnaround strategy amid activist shareholder pressure, highlighting a higher-than-expected profit driven by strong sales of the COVID-19 treatment Paxlovid. Despite reporting better-than-expected earnings and raising annual forecasts, investors expressed caution, urging for improved profitability and growth from recent acquisitions. Bourla confirmed his commitment to Pfizer's future and outlined ongoing cost-cutting measures and plans to enhance their drug pipeline.
Source: YAHOO